The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells
about
The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicityUnderground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer CellsNatural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor ActivityTumor-primed NK cells: waiting for the green lightIncreased CD112 expression in methylcholanthrene-induced tumors in CD155-deficient miceNKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple MyelomaCytotoxicity of CD56(bright) NK cells towards autologous activated CD4+ T cells is mediated through NKG2D, LFA-1 and TRAIL and dampened via CD94/NKG2ATIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.DNAM-1 control of natural killer cells functions through nectin and nectin-like proteins.DNAX accessory molecule-1 (CD226) promotes human hepatocellular carcinoma cell lysis by Vgamma9Vdelta2 T cells.Increased levels of soluble CD226 in sera accompanied by decreased membrane CD226 expression on peripheral blood mononuclear cells from cancer patients.Natural Killer Cells Response to IL-2 Stimulation Is Distinct between Ascites with the Presence or Absence of Malignant Cells in Ovarian Cancer Patients.NK cells and multiple myeloma-associated endothelial cells: molecular interactions and influence of IL-27Human Herpesvirus 8 (HHV8) sequentially shapes the NK cell repertoire during the course of asymptomatic infection and Kaposi sarcomaInterleukin 10 decreases MICA expression on melanoma cell surface.Cervical cancer cell lines expressing NKG2D-ligands are able to down-modulate the NKG2D receptor on NKL cells with functional implicationsUpdate on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies.Critical role of DNAX accessory molecule-1 (DNAM-1) in the development of acute graft-versus-host disease in miceOpportunities and limitations of natural killer cells as adoptive therapy for malignant diseaseBalancing natural killer cell activation through paired receptors.Oncogenic stress sensed by the immune system: role of natural killer cell receptorsChemotherapy-resistant osteosarcoma is highly susceptible to IL-15-activated allogeneic and autologous NK cells.Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cellsInvolvement of CD226+ NK cells in immunopathogenesis of systemic lupus erythematosusThe structural basis of ligand recognition by natural killer cell receptors.DNAM-1-based chimeric antigen receptors enhance T cell effector function and exhibit in vivo efficacy against melanoma.Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation.The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies.Immunosurveillance and therapy of multiple myeloma are CD226 dependent.Enhancement of tumor cell susceptibility to natural killer cell activity through inhibition of the PI3K signaling pathway.The Clinical and Pathological Significance of Nectin-2 and DDX3 Expression in Pancreatic Ductal Adenocarcinomas.Increased Soluble CD155 in the Serum of Cancer Patients.CD226 gene polymorphisms are associated with non-small-cell lung cancer in the Chinese Han population.Natural killer cell lines preferentially kill clonogenic multiple myeloma cells and decrease myeloma engraftment in a bioluminescent xenograft mouse model.The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myelomaDifferential loss of natural killer cell activity in patients with acute myocardial infarction and stable angina pectorisNectin-2 and DDX3 are biomarkers for metastasis and poor prognosis of squamous cell/adenosquamous carcinomas and adenocarcinoma of gallbladderHLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors.Overexpression of KIR inhibitory ligands (HLA-I) determines that immunosurveillance of myeloma depends on diverse and strong NK cell licensing.DNAM-1 promotes activation of cytotoxic lymphocytes by nonprofessional antigen-presenting cells and tumors
P2860
Q24651041-67709A89-3335-4856-9E94-C3827E6F8D13Q26751011-DBBC13D6-FEA1-4426-A776-4C896993B873Q26773135-182F43FC-663B-48F5-8DE9-D20D6AB62166Q26999306-A0956918-05B2-467E-B51F-49597DC98629Q27330218-C7102DF0-F669-4428-9D28-4741D4C03766Q28080823-03DEF20C-AE33-4EF9-AD00-2D66960CF6D4Q28731856-7A4FEEFC-A9D5-4598-AC1C-F33048DFC7EAQ30399437-62B2320B-D1E6-4443-AF0B-B803ABE6EA76Q30716850-53096EF2-BC69-4B01-84C5-B6908FADD39DQ33436859-40E8ACA1-8DA9-4E8C-A406-2B57366D2360Q33458907-6EB3836F-3FFA-431D-AAE2-0043978375C0Q33754724-9C87F23C-916E-4858-9B4C-3D1EEB078A0CQ33798745-46668D6D-6DD7-48FA-9060-DE3BD5C7C186Q34130226-B9C0BD05-3838-45EA-A5F4-598288807422Q34131549-FC73C247-F433-48E0-9920-C892588D6F76Q34153620-754FD159-2DC8-4C3D-9636-453F06177E5CQ34253548-C2176E3B-7C8B-4293-B2BD-52C33554FE5AQ34276582-B1AEA5DB-9837-45AC-93AC-7699CA0094ABQ34307792-68FF7031-2812-4AA3-B7D9-2571DCC2013CQ34465877-32EE6708-4500-4AD1-A582-27D3C3203F65Q34473267-8867C7B9-96D3-47F2-8058-D4AD210C4E7DQ34700290-6A020AFD-9A71-4121-B5D8-A2503606C83AQ34985537-1866AA8D-C570-4E8F-936F-93ED107C0D4FQ34989378-F9FC7A1C-0D2E-4BE4-93C8-5578322804E1Q35001148-CCABDDF6-F333-460F-B628-FAD20504A011Q35209066-7B8412AA-28FB-4691-AE7E-3CE775444EECQ35546925-AAEEAAD7-D40A-4C7D-BC24-7A35EFCAECF8Q35669068-4AD1B259-81FB-4910-8013-BD0E30869FC1Q35719883-978B7E6E-5E73-41BD-B584-EF5A1BC50E21Q35925485-E33248F2-C349-406C-9024-44C767A4627DQ35947249-74104C7E-2544-4F9E-92F0-D9A745B8B849Q35980806-3FA24C9D-93E1-46C5-AA6A-72E8726FC6ABQ36010404-20A25EFE-A0C8-4842-9AA2-266FB49CBBCEQ36094697-43DFDBD6-4E7C-4796-85E9-36F756C30BE2Q36414249-E3CBC707-F316-4517-86F7-00B8128FDB9DQ36464559-D63E729D-9434-4342-8056-FD9A37C29273Q36529907-7568D92C-8EEB-4764-A5CE-CBF32BF2E2BCQ36799788-0369EA94-9509-4558-B416-BFCEA5F2E701Q36821228-4198A623-00AC-4175-A698-B607E7AE5454Q37019651-557FD8AC-2D48-45FC-8FAB-6914DB747018
P2860
The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
The requirement for DNAM-1, NK ...... iated killing of myeloma cells
@ast
The requirement for DNAM-1, NK ...... iated killing of myeloma cells
@en
The requirement for DNAM-1, NK ...... iated killing of myeloma cells
@en-gb
The requirement for DNAM-1, NK ...... iated killing of myeloma cells
@nl
type
label
The requirement for DNAM-1, NK ...... iated killing of myeloma cells
@ast
The requirement for DNAM-1, NK ...... iated killing of myeloma cells
@en
The requirement for DNAM-1, NK ...... iated killing of myeloma cells
@en-gb
The requirement for DNAM-1, NK ...... iated killing of myeloma cells
@nl
prefLabel
The requirement for DNAM-1, NK ...... iated killing of myeloma cells
@ast
The requirement for DNAM-1, NK ...... iated killing of myeloma cells
@en
The requirement for DNAM-1, NK ...... iated killing of myeloma cells
@en-gb
The requirement for DNAM-1, NK ...... iated killing of myeloma cells
@nl
P2093
P50
P3181
P1433
P1476
The requirement for DNAM-1, NK ...... iated killing of myeloma cells
@en
P2093
Ann W Morgan
Faith E Davies
Gareth J Morgan
Gordon Cook
Josephine L Meade
Sarah L Mackie
Stephen J Richards
Sylvia Feyler
Tim D Holmes
P304
P3181
P356
10.1158/0008-5472.CAN-06-4230
P407
P577
2007-09-15T00:00:00Z